Department of Epidemiology , Erasmus MC, Rotterdam, The Netherlands.
Youth and Healthcare Inspectorate , Heerlen, The Netherlands.
Gut Microbes. 2020 Nov 9;12(1):1795492. doi: 10.1080/19490976.2020.1791677.
Antimicrobial drugs are known to have effects on the human gut microbiota. We studied the long-term temporal relationship between several antimicrobial drug groups and the composition of the human gut microbiota determined in feces samples.
Feces samples were obtained from a community-dwelling cohort of middle-aged and elderly individuals (Rotterdam Study). Bacterial DNA was isolated and sequenced using V3/V4 16 S ribosomal RNA sequencing (Illumina MiSeq). The time between the last prescription of several antimicrobial drug groups and the day of sampling was categorized into 0-12, 12-24, 24-48 and >48 months. The effects of the antimicrobial drug groups on the Shannon alpha-diversity (diversity), the Bray-Curtis beta-diversity (community structure), the Firmicutes/Bacteroidetes (F/B) ratio and individual genera were determined.
We studied the gut microbiota of 1413 individuals (57.5% female, median age 62.6 years). The alpha-diversity was significantly lower up to 4 years after prescriptions of macrolides and lincosamides. It was also lower in the first year after the use of beta-lactams. The community structure (beta-diversity) of the microbiota was significantly different up to 4 years for macrolides and lincosamides, the first year for beta-lactams and at least the first year for quinolones. For the F/B ratio, drugs with a high anaerobic activity shifted the ratio toward Firmicutes in the first year whereas other antimicrobial drugs shifted the ratio toward Bacteroidetes.
Use of antimicrobial drugs is associated with a shift in the composition of the gut microbiota.These effects differ in strength and duration, depending on the antimicrobial drug group used. These findings should be considered when prescribing antimicrobial drugs.
抗菌药物已知会对人体肠道微生物群产生影响。我们研究了几种抗菌药物与粪便样本中确定的人类肠道微生物群组成之间的长期时间关系。
从居住在社区的中年和老年人群(鹿特丹研究)中获得粪便样本。使用 V3/V4 16S 核糖体 RNA 测序(Illumina MiSeq)分离和测序细菌 DNA。将最后一次服用几种抗菌药物组与采样日之间的时间间隔分为 0-12、12-24、24-48 和>48 个月。确定抗菌药物组对 Shannon alpha 多样性(多样性)、Bray-Curtis beta 多样性(群落结构)、厚壁菌门/拟杆菌门(F/B)比值和个体属的影响。
我们研究了 1413 个人的肠道微生物群(57.5%为女性,中位年龄 62.6 岁)。在服用大环内酯类和林可酰胺类药物后长达 4 年内,alpha 多样性显著降低。在使用β-内酰胺类药物后的第一年也是如此。在服用大环内酯类和林可酰胺类药物的 4 年内,β-内酰胺类药物的第一年以及至少在使用喹诺酮类药物的第一年,微生物群落结构(β-多样性)明显不同。对于 F/B 比值,高厌氧活性的药物会使比值在第一年向厚壁菌门转移,而其他抗菌药物会使比值向拟杆菌门转移。
抗菌药物的使用与肠道微生物群组成的变化有关。这些影响因使用的抗菌药物组而异,强度和持续时间不同。在开处方时应考虑这些发现。